Survey of off-label anti-IL1 treatments in France: preliminary data by Koné-Paut I, Fautrel B, Galeotti C, Rossi-Semerano L

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis by Taylor, P, Blanco, R, Ikeda, K, Jia, B, Chen, YF, Walls, C, Haladyj, E, Fautrel, B

Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib by Fautrel, B, Taylor, P, Michaud, K, Patel, H, Zhu, B, Gaich, C, Guo, J, Quebe, A, Tanaka, Y

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis by Fautrel, B, Alten, R, Kirkham, B, de la Torre, I, Durand, F, Barry, J, Holzkaemper, T, Fakhouri, W, Taylor, P

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis by Tanaka, Y, Fautrel, B, Keystone, E, Ortmann, R, Zhu, B, Issa, M, Patel, H, De Bono, S, Rooney, T, Taylor, P

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM by Fautrel, B, Kirkham, B, Pope, J, Takeuchi, T, Gaich, C, Quebe, A, Zhu, B, De La Torre, I, De Leonardis, F, Taylor, P

Physician and patient attitudes towards treat-to-target, its implementation and stated treatment goals in patients with rheumatoid arthritis in a real-world setting across Europe by Fautrel, B, Caporali, R, Holdsworth, E, Donaghy, B, Khalid, M, Moore, M, Van Beneden, K, Piette, Y, Romero-Yuste, S, Broen, J, Taylor, PC

Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity, and... by Taylor, PC, Fautrel, B, Piette, Y, Romero-Yuste, S, Broen, J, Welcker, M, Howell, O, Rottier, E, Zignani, M, Van Beneden, K, Caporali, R, Alten, R

Impact of filgotinib on pain control in the phase 3 FINCH studies by Taylor, PC, Kavanaugh, A, Nash, P, Pope, J, Pongratz, G, Fautrel, B, Alten, R, Hasegawa, K, Rao, S, de Vries, D, Stiers, P-J, Watson, C, Westhovens, R

Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA by Van De Laar, M, Pope, J, Lee, Y, Fautrel, B, Ikeda, K, Quebe, A, Zhang, X, Gaich, C, De Leonardis, F, Lisse, J, Workman, J, Taylor, P

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patient... by Fautrel, B, Zhu, B, Taylor, P, van de Laar, M, Emery, P, De Leonardis, F, Gaich, C, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patient... by Fautrel, B, Zhu, B, Taylor, PC, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, CL, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial by Taylor, P, Lee, Y, Fleischmann, R, Takeuchi, T, Perkins, E, Fautrel, B, Zhu, B, Quebe, A, Gaich, C, Zhang, X, Dickson, C, Schlichting, D, Patel, H, Durand, F, Emery, P

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis by Emery, P, Dudler, J, Smolen, J, Zerbini, C, Burmester, G, Fautrel, B, Van Der Laar, M, Fleischmann, R, Fakhouri, W, De Leonardis, F, Zhu, B, Kadziola, Z, De La Torre, I, Perrier, C, Taylor, P

“Evolving the management of RA” programme: educational tools to support daily practice by Burmester, G, Alvaro-Gracia, JM, Betteridge, N, Calvo-Alen, J, Combe, B, Durez, P, Ferreira, RJO, Fautrel, B, Iagnocco, A, Montecucco, C, Østergaard, M, Ramiro, S, Rubbert-Roth, A, Stamm, T, Szekanecz, Z, Taylor, PC, van de Laar, M

Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools by Burmester, GR, Álvaro-Gracia, JM, Betteridge, N, Calvo Alén, J, Combe, B, Durez, P, Fautrel, B, Ferreira, RJO, Gabay, C, Iagnocco, A, Montecucco, C, Østergaard, M, Ramiro, S, Rubbert-Roth, A, Stamm, T, Szekanecz, Z, Taylor, PC, Van de Laar, M

Evolving the management of rheumatoid arthritis (eRA) through development of practical and educational tools by Van De Laar, M, Álvaro-Gracia, J, Betteridge, N, Calvo Alén, J, Combe, B, Durez, P, Ferreira, R, Fautrel, B, Gabay, C, Iagnocco, A, Montecucco, C, Østergaard, M, Ramiro, S, Rubbert-Roth, A, Stamm, T, Szekanecz, Z, Taylor, P, Burmester, G

Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries by Sousa, M, Lubrano, E, Smolen, JS, Gorlier, C, de Wit, M, Coates, LC, Kalyoncu, U, Ruyssen-Witrand, A, Leung, Y-Y, Scrivo, R, Cañete, JD, Palominos, P, Meisalu, S, Balanescu, A, Kiltz, U, Zehra Aydin, S, Gaydukova, I, Dernis, E, Fautrel, B, Orbai, A-M, Gossec, L